QoL Superior With Atezolizumab/Bevacizumab Versus Sorafenib in Frontline HCC
Analysis of patient-reported outcomes from the phase III IMbrave 150 study showed meaningful benefits in quality of life, functioning, and key symptoms with atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in patients with unresectable hepatocellular carcinoma.
Triplet and Doublet Regimens Outperform Standard of Care on Survival, QoL in BRAF+ CRC
Encorafenib plus cetuximab with or without binimetinib demonstrated longer maintenance of quality of life on patient-reported assessments over current standard of care in the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer.
Dr. Villanueva on Eliminating Tumor Heterogeneity in Patients With HCC
January 27th 2020Augusto Villanueva, MD, an assistant professor of the Division of Liver Diseases at the Tisch Cancer Institute of Icahn School of Medicine at Mount Sinai, discusses mutations and gene signatures for patients with hepatocellular carcinoma, a topic he presented at the 2020 Gastrointestinal Cancers Symposium.
Dr. O'Reilly on Veliparib/Chemotherapy Triplet in Germline BRCA/PALB2+ Pancreatic Cancer
January 27th 2020Eileen M. O’Reilly, MD, discusses the randomized phase II trial of gemcitabine and cisplatin versus gemcitabine and cisplatin and veliparib in patients with pancreas adenocarcinoma harboring a known germline BRCA or PALB2 mutation, which was presented at the 2020 Gastrointestinal Cancers Symposium.
Regorafenib/TAS-102 Induces Clinically Meaningful DCR in Refractory Metastatic CRC
Third-line treatment of patients with metastatic colorectal cancer using regorafenib plus oral fluoropyrimidine TAS-102 provides clinically meaningful disease control with toxicities consistent with the safety profiles of either agent, according to data from the phase I dose-escalation trial REMETY presented at the 2020 Gastrointestinal Cancers Symposium.
Second-Line Ramucirumab Improves OS in AFP-Elevated HCC, Regardless of Disease Stage
Ramucirumab as second-line therapy after sorafenib induces improved overall survival compared with placebo, irrespective of Barcelona Clinic Liver Cancer stage, in patients with intermediate-stage hepatocellular carcinoma and an elevated baseline level of alpha fetoprotein.
Dr. Wainberg on Impact of PD-L1 Status in Gastric/GEJ Cancer Treatment
January 26th 2020Zev A. Wainberg, MD discusses the efficacy findings of pembrolizumab monotherapy versus chemotherapy for patients with PD-L1–positive advanced gastric and gastroesophageal junction cancer of high combined positive score in cohort 1 of the phase II KEYNOTE-059 and in the phase III KEYNOTE-061 and KEYNOTE-062 studies.
Nivolumab Triplet Elicits Clinically Meaningful Responses in Advanced HCC
January 25th 2020The triplet regimen of nivolumab (Opdivo), ipilimumab (Yervoy), and cabozantinib (Cabometyx) achieved clinically meaningful responses in patients with advanced hepatocellular carcinoma who were either sorafenib (Nexavar)-naïve, or resistant to or intolerant of sorafenib.
Frontline Lenvatinib with Subsequent Therapy Improves Survival in Unresectable HCC
Patients with unresectable hepatocellular carcinoma who were randomized to first-line lenvatinib (Lenvima), compared with sorafenib (Nexavar), and received subsequent anticancer procedures experienced prolonged overall survival.
Addition of Cabozantinib to Ipi/Nivo Shows Promising Antitumor Activity in Advanced HCC
The triplet combination of cabozantinib, nivolumab, and ipilimumab induced higher response rates, progression-free survival, and overall survival compared with nivolumab plus cabozantinib in patients with advanced hepatocellular carcinoma.
Pembrolizumab Shows Enhanced Efficacy in High PD-L1 Gastric Cancer
Pembrolizumab monotherapy in the first and later lines of therapy leads to more durable responses and meaningfully improves overall survival compared with chemotherapy in patients with advanced gastric/gastroesophageal junction cancer with a high number of PD-L1–expressing cells in the tumor, lymphocytes, and macrophages.
Durvalumab/Tremelimumab Combo Improves Efficacy in Refractory CRC
The combination use of durvalumab and tremelimumab plus best supportive care prolonged median overall survival by 2.5 months compared with supportive care alone in patients with advanced refractory colorectal cancer.
Regorafenib Extends PFS in Locally Advanced Biliary Tract Cancer
The oral multi-kinase inhibitor regorafenib extended progression-free survival in patients with metastatic or unresectable biliary tract cancer who were previously treated with gemcitabine and a platinum-based chemotherapy.
Dabrafenib/Trametinib Combo Induces High Responses in BRAF V600E-Mutant Biliary Tract Cancer
The combination of dabrafenib and trametinib induced responses in nearly half of patients with BRAF V600E–mutated biliary tract cancer who participated in a phase II basket trial that enrolled patients with BRAF V600E–mutated rare cancers.
SM-88 Achieves Encouraging Clinical Benefit Rate in Metastatic Pancreatic Cancer
The novel oral anticancer regimen known as SM-88, which consists of a tyrosine derivative, an mTOR inhibitor, a CYP3a4 inducer, and an oxidative stress catalyst, has promising efficacy with no meaningful toxicity in patients with metastatic pancreatic cancer who have progressed on at least 1 prior line of therapy.